Welcome to our dedicated page for Biofrontera news (Ticker: BFRI), a resource for investors and traders seeking the latest updates and insights on Biofrontera stock.
Biofrontera Inc. (NASDAQ: BFRI) is a U.S.-based biopharmaceutical company specializing in dermatology and photodynamic therapy (PDT). Its news flow centers on the commercialization and clinical development of Ameluz® and the RhodoLED® lamp series for the treatment of actinic keratoses and other skin conditions.
On this page, readers can follow company announcements related to financial results, such as quarterly and annual revenue updates, as well as business updates describing trends in Ameluz® sales and operating expenses. Biofrontera frequently reports on revenue performance, gross margin developments, and the impact of its strategic agreements on its financial profile.
News items also highlight clinical and regulatory milestones. These include database locks and completion of clinical studies in actinic keratosis on peripheral body areas, Phase 1 pharmacokinetics data, Phase 3 results in superficial basal cell carcinoma, and Phase 2 progress in acne vulgaris. The company uses press releases to describe how these data support supplemental New Drug Applications and future Phase 3 programs.
In addition, Biofrontera issues updates on strategic transactions and capital markets activity, such as the acquisition of all U.S. rights to Ameluz® and RhodoLED® from Biofrontera AG, changes to royalty and earnout structures, private placements of convertible preferred stock, and the divestiture of its Xepi® antibiotic cream license. Regulatory notices regarding Nasdaq listing compliance and participation in investor conferences are also part of the company’s regular news flow.
Investors and observers who want to track developments in dermatologic photodynamic therapy, label expansion efforts for Ameluz®-PDT, and Biofrontera’s financial and strategic progress can use this news feed as a centralized source of company-issued updates.
Biofrontera Inc. (BFRI) has achieved a significant milestone in its Phase 3 study of Ameluz-PDT for treating superficial Basal Cell Carcinoma (sBCC), with the last patient completing the 1-year follow-up in December 2024. The study, involving 187 patients, demonstrated highly statistically significant results (p <0.0001) for all primary and secondary endpoints in October 2024.
The double-blind, randomized, placebo-controlled trial evaluated patients with confirmed sBCC who received either Ameluz-PDT or placebo-PDT treatments. The company plans to submit an sNDA to the FDA in Q3 2025, including the one-year follow-up data. While this data supports the FDA submission, patients will be monitored for a total of five years due to risks of local recurrence.
BCC represents the most common skin cancer in the US, with over 3 million cases annually, making this potential treatment expansion significant for Biofrontera's market presence.
Biofrontera Inc. (BFRI) announced the successful placement of its 100th RhodoLED® XL Lamp in the US market since its commercial launch in June 2024. The device, FDA-approved in 2022 for use with Ameluz® gel for photodynamic therapy (PDT) of actinic keratoses, has seen rapid adoption with more than 10% of Ameluz-using offices installing the system.
The RhodoLED XL features more LED panels than its predecessor BF-RhodoLED, enabling treatment of larger surface areas in a single session. Dr. Aaron Hoover of Front Range Dermatology highlighted the lamp's design, maneuverability, and enhanced patient throughput. Following FDA approval in October 2024, physicians can now use up to 3 tubes of Ameluz® in one treatment, maximizing the benefits of the larger illumination area.
Biofrontera Inc. (Nasdaq:BFRI), a biopharmaceutical company focused on photodynamic therapy (PDT), has announced its participation in The Benchmark Company's 13th Annual Discovery One-on-One Investor Conference. The event will take place on December 11th, 2024 at the New York Athletic Club in New York City.
The conference provides a platform for emerging growth companies to connect with institutional and individual investors through one-on-one meetings. Biofrontera will engage in individual meetings with investors and analysts throughout the day. Interested parties can schedule meetings through the provided registration link.
Biofrontera (Nasdaq: BFRI) has completed a private placement of a $4.2 million senior secured convertible note with its principal shareholders. The note matures on November 22, 2027, with a 10% annual PIK interest rate and is secured by company assets. The note is convertible to common shares at $0.78 per share at holder's discretion, or automatically if the 10-day VWAP exceeds $2.50. The financing includes restrictive covenants limiting the company's ability to create liens, pay dividends, incur debt, or enter affiliate transactions. Proceeds will support general operations and strategic investments, including commercial and clinical development initiatives.
Biofrontera reported Q3 2024 revenues of $9.0 million, up 1.5% from Q3 2023, with potential 19% growth impacted by Hurricane Milton delays. Nine-month revenues reached $24.8 million, showing 5.6% growth. Ameluz achieved record volume in September 2024, while SG&A expenses decreased 14% year-over-year. The company successfully launched RhodoLED XL with 39 installations since June 2024. Notable developments include FDA approval to increase Ameluz dosage to three tubes per treatment and highly significant Phase 3 sBCC study results showing 75.9% histological clearance versus 19% with placebo.
Biofrontera (Nasdaq: BFRI), a biopharmaceutical company focused on PDT development and commercialization, will release its financial results for Q3 2024 and the nine months ended September 30, 2024, after market close on November 13, 2024. The company will host a conference call to discuss the results on November 14, 2024, at 10:00 AM ET. The call will be accessible via phone and webcast for both U.S. and international participants.
Biofrontera announced significant results from its Phase 3 study of Ameluz®-PDT for treating superficial basal cell carcinoma (sBCC). The study involved 187 patients and showed 65.5% success rate with Ameluz®-PDT compared to 4.8% with placebo in achieving complete clinical and histological clearance. Secondary endpoints were also highly significant (p<0.0001), with 64.1% of Ameluz®-PDT patients achieving total clearance of all sBCC lesions versus 4.8% for placebo. Patient satisfaction was notable, with 64.3% rating the treatment as very good and 22.2% as good. The company plans to submit FDA documentation in Q2/Q3 2025 after completing the one-year follow-up phase in December.
Biofrontera Inc. (Nasdaq: BFRI) has announced the database lock for its Phase 3 study ALA-BCC-CT013, evaluating Ameluz®-Photodynamic Therapy (PDT) for treating superficial Basal Cell Carcinoma (sBCC). This marks the end of data collection for the treatment phase, with analysis now underway. The study, involving 186 patients, is the first Phase 3 PDT trial for sBCC in the United States.
Key points:
- Double-blind, randomized, placebo-controlled multi-center study
- Primary endpoint: complete clinical and histological clearance of target BCC lesion
- Interim results expected November 2024
- FDA submission targeted for Q1 2025, including 1-year follow-up data
If approved, this would expand Biofrontera's label from premalignant applications to treating cutaneous malignancy, advancing their goal of becoming market leaders in PDT.
The FDA has approved Biofrontera’s sNDA to increase the maximum dosage of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10%, from one to three tubes per treatment. This approval enhances the treatment of actinic keratosis (AK) on the face and scalp using Ameluz®-PDT with the BF-RhodoLED or RhodoLED XL lamp. The decision is based on two Phase 1 safety studies involving 116 patients, which confirmed that the increased dosage maintains safety and efficacy levels. This approval allows healthcare providers to treat larger or multiple areas more effectively, improving convenience for both providers and patients. Biofrontera is working with Medicare and commercial payers to secure reimbursement for this update.
Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company focused on commercializing dermatologic products, has announced its participation in the 3rd Annual ROTH Healthcare Opportunities Conference. The event will take place at the Metropolitan Club in New York, NY.
Key details of Biofrontera's presentation include:
- Date: October 9, 2024
- Time: 12:30 - 1:10 PM ET
- Format: Live Presentation
The company has also made provisions for one-on-one meetings during the conference. Interested parties are advised to contact their Roth representative to schedule these meetings.
This presentation offers an opportunity for Biofrontera to showcase its developments in the dermatologic products sector to potential investors and industry professionals.